Expert: Research Shows Selenium To Be Effective Treatment Against Breast Cancer
October 20, 2014
Research on attaching selenium to the leading clinical chemotherapeutic monoclonal
antibody for a type of breast cancer shows it can more effectively kill the cancer
Almost a quarter of a million people were diagnosed with breast cancer this year,
while another 3 million are living with the disease. Although the cure rate for breast
cancer is high – it has an 89 percent 5-year survival rate – a large number of patients
have a recurrence of their cancer. Breast Cancer Awareness Month highlights the continuing
research on this type of cancer, the second most common cancer in the United States.
Julian Spallholz, a professor of nutritional sciences at Texas Tech University, has studied the effects of selenium on several types of cancer. His research on
attaching selenium to the leading clinical chemotherapeutic monoclonal antibody for
a type of breast cancer shows it can more effectively kill the cancer cells.
Julian Spallholz, professor of nutritional sciences, (806) 834-7406 or email@example.com
- About 20 percent of breast cancer patients have overexpressed growth receptors, known
as Her2+ receptors, on the cancer cells, which cause uncontrolled tumor growth. The
clinical treatment options on the market today focus on those receptors.
- This treatment consists of monoclonal antibodies, which scientists have developed
to target cancer cells such as Her2+. This has proven to be effective, but a patient's
cancer can often develop resistance to the drug.
- Selenium, when attached to a monoclonal antibody presently used to treat breast cancer,
has shown greater success in destroying cancer cells in a patient who has developed
resistance to the chemotherapy.
- “The selenium research conducted by students and colleagues over the years and with
the data from this commercial monoclonal antibody leads one to the longer term view
that the redox technology produced by selenium and employed here is applicable to
many medical applications. Additional applications include other clinical cancer monoclonal
antibodies, targeting polypeptides, aptamers and possibly antibiotics. The attached
selenium chemistry has the effect of changing the pharmacologic profile of a targeting
Find Texas Tech news, experts and story ideas at Texas Tech Today Media Resources or follow us on Twitter.